Pacira BioSciences financials
$25.65+1.02%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $192.4M | $177.4M | $196.9M | $179.5M | $181.1M | $168.9M | $187.3M | $168.6M | $178.0M | $167.1M | $181.2M | $163.9M |
| Gross profit | $148.2M | $141.0M | $156.6M | $145.2M | $140.2M | $134.6M | $147.4M | $129.7M | $133.8M | $119.7M | $133.6M | $124.2M |
| Gross margin | 77.0% | 79.5% | 79.5% | 80.9% | 77.4% | 79.7% | 78.7% | 76.9% | 75.1% | 71.6% | 73.7% | 75.8% |
| Operating income | $4.3M | $6.9M | $2.3M | $6.4M | $8.5M | $2.0M | $24.7M | -$139.5M | $28.2M | $13.2M | $33.2M | $17.7M |
| Net income | $4.7M | $2.9M | $1.6M | $5.4M | -$4.8M | $4.8M | $16.0M | -$143.5M | $18.9M | $9.0M | $24.9M | $10.9M |
| Net margin | 2.4% | 1.6% | 0.8% | 3.0% | −2.7% | 2.8% | 8.6% | −85.1% | 10.6% | 5.4% | 13.7% | 6.6% |
| Diluted EPS | $0.12 | $0.07 | $0.04 | $0.12 | $-0.11 | $0.10 | $0.44 | $-3.11 | $0.39 | $0.19 | $0.43 | $0.23 |
| EBITDA | $26.2M | $28.2M | $23.7M | $27.6M | $36.0M | $23.2M | $45.9M | $44.0M | $47.1M | $31.6M | $34.0M | $39.5M |
| Operating cash flow | $57.5M | $25.7M | $43.7M | $60.8M | $12.0M | $35.5M | $33.1M | $53.9M | $53.2M | $49.1M | $47.2M | $41.6M |
| Free cash flow | $56.1M | $23.0M | $43.5M | $57.0M | $9.3M | $26.9M | $31.0M | $49.8M | $51.6M | $46.3M | $45.4M | $38.3M |
| Diluted shares | 40.3M | 40.9M | 43.7M | 44.5M | 45.5M | 46.5M | 36.1M | 46.1M | 50.5M | 52.2M | 57.8M | 52.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $205.9M | $144.3M | $158.5M | $147.6M | $300.5M | $283.6M |
| Short-term investments | $45.2M | $57.9M | $79.9M | $98.7M | $145.4M | $210.0M |
| Total debt | $363.1M | $367.7M | $372.2M | $376.7M | $580.5M | $583.4M |
| Total assets | $1.24B | $1.21B | $1.26B | $1.30B | $1.54B | $1.59B |
| Total liabilities | $572.0M | $554.6M | $571.8M | $570.4M | $779.5M | $788.1M |
| Shareholders' equity | $672.0M | $653.9M | $693.1M | $727.2M | $757.8M | $798.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology